Prices delayed by 15 minutes
Next earnings report: 29 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
DexCom, Inc. trades on Nasdaq under the ticker DXCM. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks DXCM has traded between 54.11 $ and 92.59 $. As of 09 October 2026 the price stood 78.74 % of the way from the 52-week low to the high.
Over one year DXCM shares rose 27.84 %; over six months they rose 28.52 %. Volatility over 90 days is 38.88 %. Dividends are not included: this is price change only, as of 09 October 2026.
DXCM trades at a price-to-earnings ratio of 35.0, above the sector median of 24.8. Price to sales is 6.8, above the sector median of 3.9. Price to book is 11.0, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 84.01 | 84.54 | 83.08 | 84.41 | 4M |
| 07 October 2026 | 83.81 | 85.70 | 83.74 | 84.30 | 3M |
| 06 October 2026 | 86.28 | 86.75 | 82.86 | 83.39 | 4M |
| 05 October 2026 | 84.75 | 87.12 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
DexCom makes sensors that measure blood sugar continuously and send the readings to a phone.
The device frees a person with diabetes from finger pricks several times a day: the sensor is worn on the body and shows not only the current value but the direction of change. That improves the quality of disease control, not merely convenience, which is why physicians prescribe such systems ever more widely.
The economics are effectively a subscription: the sensor is replaced every few days, so revenue recurs and the number of active users matters more than devices sold. The market is expanding from type 1 diabetes into type 2, where patients are an order of magnitude more numerous. Risks: insurer reimbursement decisions, price pressure and competition from the maker of a similar system. The company pays no dividend.
Address:6340 SEQUENCE DRIVE, SAN DIEGO, CA, 92121, US
DexCom, Inc. reported revenue of 4.8B $ and net income of 930M $ over the last four quarters. Net margin is 19.31 %. Revenue changed by +16.15 % year over year. Earnings per share are 2.33 $. Market capitalisation is 32.6B $.
DXCM has a return on equity of 31.47 %, above the sector median of −41.68 %. Return on assets is 14.03 %, above the sector median of −32.11 %. Operating margin is 21.45 %, above the sector median of −26.84 %.
| 325M |
| MDLNMedline Inc. | 36.26 | +1.45 % | 297M |
| RMDResMed Inc. | 230.43 | +1.63 % | 276M |
| PODDInsulet Corporation | 135.28 | +0.60 % | 244M |
| WSTWest Pharmaceutical Services, Inc. | 368.78 | +1.52 % | 207M |
| 84.75 |
| 86.90 |
| 3M |
| 02 October 2026 | 86.67 | 86.67 | 84.80 | 85.36 | 2M |
| 01 October 2026 | 86.46 | 87.70 | 85.81 | 86.23 | 3M |
| 30 September 2026 | 86.21 | 86.75 | 85.26 | 86.29 | 3M |
| 29 September 2026 | 86.63 | 87.03 | 85.24 | 86.64 | 3M |
| 28 September 2026 | 86.87 | 87.34 | 85.27 | 86.68 | 3M |
| 25 September 2026 | 87.38 | 87.64 | 86.36 | 86.62 | 2M |
| 24 September 2026 | 87.68 | 88.00 | 86.88 | 87.47 | 2M |
| 23 September 2026 | 89.50 | 90.05 | 87.36 | 87.73 | 4M |
| 22 September 2026 | 89.12 | 90.39 | 88.18 | 89.53 | 7M |
| 21 September 2026 | 88.83 | 89.68 | 88.33 | 89.17 | 4M |
| 18 September 2026 | 87.83 | 89.92 | 87.39 | 89.35 | 15M |
| 17 September 2026 | 87.54 | 88.26 | 87.17 | 87.93 | 3M |
| 16 September 2026 | 86.05 | 88.79 | 86.05 | 87.34 | 4M |
| 15 September 2026 | 84.04 | 87.36 | 83.26 | 86.45 | 6M |
| 14 September 2026 | 83.92 | 84.98 | 83.76 | 84.68 | 3M |
| 11 September 2026 | 84.65 | 85.82 | 82.83 | 83.03 | 3M |